Short Interest in Femasys Inc. (NASDAQ:FEMY) Decreases By 7.1%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 489,100 shares, a decline of 7.1% from the October 31st total of 526,700 shares. Currently, 2.3% of the company’s shares are short sold. Based on an average daily volume of 172,600 shares, the days-to-cover ratio is presently 2.8 days.

Analyst Upgrades and Downgrades

FEMY has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Femasys in a research report on Tuesday. Chardan Capital lowered their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Institutional Trading of Femasys

A number of institutional investors have recently modified their holdings of the stock. CM Management LLC lifted its position in shares of Femasys by 6.3% during the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after buying an additional 25,000 shares during the last quarter. Aljian Capital Management LLC acquired a new position in shares of Femasys in the third quarter valued at approximately $27,000. XTX Topco Ltd raised its stake in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the period. 65.27% of the stock is currently owned by institutional investors.

Femasys Stock Performance

Shares of FEMY traded down $0.02 during mid-day trading on Tuesday, hitting $1.08. 123,052 shares of the company’s stock were exchanged, compared to its average volume of 325,954. The company has a 50-day simple moving average of $1.14 and a 200 day simple moving average of $1.12. Femasys has a 52 week low of $0.73 and a 52 week high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. On average, equities research analysts anticipate that Femasys will post -0.84 EPS for the current fiscal year.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.